Leah Lawrence

DocwireNews

The bispecific T-cell engager tarlatamab show promising efficacy in patients with small cell lung cancer (SCLC) both with and without baseline brain metastasis, according to results of a subgroup analysis of the DeLLphi-301 trial presented at the 2024 American Society of Clinical Oncology Annual Meeting.
“The efficacy and the safety of tarlatamab is exactly the same in patients with and without stable, treated brain metastases at baseline,” said study presenter Anne-Marie C. Dingemans, MD, PhD, of Erasmus MC Cancer Institute, the Netherlands.
The phase 2 study enrolled 186 patients with SCLC. Patients were randomly assigned to receive tarlatamab 10 mg or tarlatamab 100 mg during the dose evaluation stage, with tarlatamab 10 mg selected for dose expansion.
Initial results of DeLLphi-301 showed an overall response rate (ORR) of 40% with a median progression-free survival of 4.9 months and a median overall survival (OS) of 14.3 months. These data were the basis for the <a href="https://www.docwirenews.com/post/fda-grants-accelerated-approval-to-tarlatamab-dlle-for-extensive-stage-sclc" target="_blank" rel="noopener">May 2024 FDA approval</a> of tarlatamab.
Dr. Dingemans presented results from a subgroup analysis of 100 patients treated with tarlatamab 10 mg.  Of these 100 patients, 23 had baseline brain metastases. Only patients with confirmed brain metastases at baseline had mandated surveillance CNS imaging.
Tarlatamab demonstrated durable responses with promising survival, regardless of the presence of treated, stable brain metastases at baseline.
With a median follow-up of 10.6 months, the ORR was 52% in patients with brain metastases, compared with 38% in patients without brain metastases. The median duration of response was not reached in either group.
The median PFS was 6.7 months for patients with brain metastases compared with 4.0 months for those without. The median OS was an “encouraging” 14.3 months in patients with baseline brain metastases, Dr. Dingemans said.
Treatment-related adverse events were comparable between the study arms. Any grade of immune effector cell-associated neurotoxicity syndrome (ICANS) and associated neurological events occurred in 3% of patients with brain metastases and 5% of patients without brain metastases. No grade 3 or worse ICANS occurred.
A post-hoc analysis of intracranial activity for the combined 10 mg and 100 mg cohorts of patients with baseline CNS lesions of ≥10 mm showed CNS tumor shrinkage of at least 30% in 59% of patients, with intracranial disease control in 94%.
According to Dr. Dingemans, these results support further study of tarlatamab in patients with previously treated SCLC, regardless of brain metastases at baseline.
Reference
Dingemans A-M C, Ahn M-J, Blackhall FH, et al. <a href="https://meetings.asco.org/abstracts-presentations/232383" target="_blank" rel="noopener">DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)—Efficacy and safety analyzed by presence of brain metastasis</a>. Presented at the 2024 American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2024, Chicago, Illinois.

Katy Marshall

Determining Prognosis for Patients With Metastatic Grade 1 GEP-NETs

GEP-NETs

Katie Kosko

ALINA Trial Analyzes Impact of Alectinib on Health-Related Quality of Life in ALK-Positive NSCLC

ASCO 2024: Focus on Lung Cancer

Real-World Analysis of Gemcitabine Plus Cisplatin, Durvalumab as a First-Line Treatment in BTC

Bile Duct Cancer

Latest News

DeLLphi-301 Analysis: Tarlatamab Is Active in SCLC, Regardless of Baseline Brain Metastases

The bispecific T-cell engager tarlatamab show promising efficacy in patients with small cell lung cancer (SCLC) both with and without baseline brain metastasis.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Onc Brothers Event

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Diabetes

Oncology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Career Center

Expert Interviews

Subscribe